31.10
price down icon1.21%   -0.38
after-market アフターアワーズ: 31.55 0.45 +1.45%
loading
前日終値:
$31.48
開ける:
$31.48
24時間の取引高:
2.02M
Relative Volume:
1.61
時価総額:
$2.44B
収益:
$866.00K
当期純損益:
$-283.65M
株価収益率:
-7.2885
EPS:
-4.267
ネットキャッシュフロー:
$-226.25M
1週間 パフォーマンス:
-18.67%
1か月 パフォーマンス:
-24.55%
6か月 パフォーマンス:
-1.83%
1年 パフォーマンス:
+23.17%
1日の値動き範囲:
Value
$30.65
$31.70
1週間の範囲:
Value
$30.39
$41.62
52週間の値動き範囲:
Value
$22.10
$45.14

Celldex Therapeutics Inc Stock (CLDX) Company Profile

Name
名前
Celldex Therapeutics Inc
Name
セクター
Healthcare (1067)
Name
電話
908-200-7500
Name
住所
53 FRONTAGE ROAD, HAMPTON
Name
職員
198
Name
次回の収益日
2026-11-09
Name
最新のSEC提出書
Name
CLDX's Discussions on Twitter

Compare CLDX vs VRTX, REGN, MRNA, ARGX, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
CLDX icon
CLDX
Celldex Therapeutics Inc
31.10 2.44B 866.00K -283.65M -226.25M -4.267
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
526.19 133.37B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
788.04 81.13B 14.92B 4.42B 3.79B 41.04
MRNA icon
MRNA
Moderna Inc
198.88 79.40B 2.23B -3.19B -1.60B -8.1462
ARGX icon
ARGX
Argen X Se Adr
959.49 60.03B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
204.97 43.93B 742.00K -1.37B -1.07B -7.0731

Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-04-20 アップグレード Barclays Underweight → Overweight
2026-03-23 アップグレード Wolfe Research Peer Perform → Outperform
2025-10-21 開始されました Mizuho Outperform
2025-10-13 開始されました Barclays Underweight
2025-04-28 開始されました Canaccord Genuity Buy
2025-03-20 開始されました Morgan Stanley Overweight
2025-02-13 開始されました UBS Buy
2024-10-07 開始されました Citigroup Buy
2024-09-30 開始されました Goldman Neutral
2024-09-27 ダウングレード Wolfe Research Outperform → Peer Perform
2024-06-18 開始されました Stifel Buy
2024-06-11 開始されました Wolfe Research Outperform
2023-12-20 開始されました TD Cowen Outperform
2023-11-10 アップグレード Wells Fargo Underweight → Equal Weight
2023-08-22 開始されました Wells Fargo Underweight
2021-09-17 開始されました Jefferies Buy
2021-09-10 開始されました SVB Leerink Outperform
2021-07-22 開始されました Guggenheim Buy
2020-02-21 開始されました Cantor Fitzgerald Overweight
2017-08-01 再開されました H.C. Wainwright Buy
2016-11-07 開始されました Aegis Capital Buy
2016-03-08 ダウングレード Jefferies Buy → Hold
2016-03-07 ダウングレード Guggenheim Buy → Neutral
2016-03-07 ダウングレード Leerink Partners Outperform → Mkt Perform
2016-03-07 ダウングレード Wedbush Outperform → Neutral
2016-03-01 開始されました H.C. Wainwright Buy
2015-08-11 繰り返されました Brean Capital Buy
2015-08-11 繰り返されました Oppenheimer Outperform
2015-08-11 繰り返されました ROTH Capital Buy
2015-06-02 繰り返されました WBB Securities Strong Buy
2014-11-17 繰り返されました ROTH Capital Buy
2014-03-04 繰り返されました Oppenheimer Outperform
2013-07-08 繰り返されました Cantor Fitzgerald Buy
2013-03-08 繰り返されました Cantor Fitzgerald Buy
2013-02-26 繰り返されました Oppenheimer Outperform
2013-01-10 繰り返されました Cantor Fitzgerald Buy
2012-10-02 繰り返されました Oppenheimer Outperform
2012-09-14 繰り返されました Cantor Fitzgerald Buy
すべてを表示

Celldex Therapeutics Inc (CLDX) 最新ニュース

pulisher
Sep 25, 2026

Yaron Werber: Celldex's Urticaria Drug Won't Carry a Black Box; Amgen Maps a $25 Billion Sjogren's Market - finance.biggo.com

Sep 25, 2026
pulisher
Sep 25, 2026

Is Celldex Therapeutics, Inc. (CLDX) the Healthcare Stocks Stock Everyone's About to Talk About? - Kalkine Media

Sep 25, 2026
pulisher
Sep 24, 2026

What Do Positive Barzolvolimab Results Mean for Celldex (NASDAQ:CLDX)? - Kalkine Media

Sep 24, 2026
pulisher
Sep 23, 2026

H.C. Wainwright Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $64 - Moomoo

Sep 23, 2026
pulisher
Sep 23, 2026

Celldex's price target jumps to $88 after positive Phase III trial for chronic urticaria drug. - Pluang

Sep 23, 2026
pulisher
Sep 23, 2026

Leerink Partners maintains Outperform rating on Celldex Therapeutics, $88 price target - TradingView

Sep 23, 2026
pulisher
Sep 23, 2026

Can Celldex (CLDX) Overcome Its Heavy Burn Rate for Long-Term Success? - Yahoo Finance

Sep 23, 2026
pulisher
Sep 23, 2026

The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte - Yahoo Finance

Sep 23, 2026
pulisher
Sep 22, 2026

Celldex Therapeutics upgraded to Buy after posi... - Pluang

Sep 22, 2026
pulisher
Sep 22, 2026

Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous UrticariaSlideshow (NASDAQ:CLDX) 2026-09-22 - Seeking Alpha

Sep 22, 2026
pulisher
Sep 22, 2026

Crude Oil Down Over 1%; Thor Industries Shares Gain After Q4 Results - Benzinga

Sep 22, 2026
pulisher
Sep 22, 2026

Celldex's Barzolvolimab Hits Mark in Two Phase 3 Trials for Chronic Hives - finance.biggo.com

Sep 22, 2026
pulisher
Sep 22, 2026

CLDX Stock Slumps 11% – This Analyst Sees Nearly 90% Upside, Calls Phase 3 Trial Safety Concerns ‘Misplaced’ - tradingview.com

Sep 22, 2026
pulisher
Sep 22, 2026

Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease - Benzinga

Sep 22, 2026
pulisher
Sep 22, 2026

Celldex Therapeutics Shares Fall After Phase 3 Readout Despite Positive Trial Results - Quiver Quantitative

Sep 22, 2026
pulisher
Sep 22, 2026

4 Biotech Stocks With Key Clinical Readouts Expected This Fall - theglobeandmail.com

Sep 22, 2026
pulisher
Sep 22, 2026

Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable Responses - Yahoo Finance

Sep 22, 2026
pulisher
Sep 22, 2026

Celldex sinks as safety concerns cloud immune drug results - Yahoo Finance

Sep 22, 2026
pulisher
Sep 22, 2026

Celldex shares slip 15% as safety concerns cloud skin drug trial win - The Economic Times

Sep 22, 2026
pulisher
Sep 22, 2026

Celldex's barzolvolimab hits primary and secondary endpoints in twin Phase III CSU trials - The Pharma Letter

Sep 22, 2026
pulisher
Sep 22, 2026

Celldex Shares Rise 8% as Barzolvolimab Meets Primary Endpoints in Two Phase 3 Trials - Yahoo Finance

Sep 22, 2026
pulisher
Sep 22, 2026

Celldex stock falls after hives trial data (CLDX:NASDAQ) - Seeking Alpha

Sep 22, 2026
pulisher
Sep 22, 2026

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

Sep 22, 2026
pulisher
Sep 22, 2026

Celldex reports positive phase 3 trial results for CSU drug By Investing.com - Investing.com Canada

Sep 22, 2026
pulisher
Sep 22, 2026

Celldex reports strong Phase 3 data in urticaria - TipRanks

Sep 22, 2026
pulisher
Sep 22, 2026

Celldex Therapeutics' Barzolvolimab Meets Phase 3 Endpoints in Two Urticaria Trials - marketscreener.com

Sep 22, 2026
pulisher
Sep 22, 2026

Celldex stock rises after positive phase 3 trial results By Investing.com - Investing.com Canada

Sep 22, 2026
pulisher
Sep 22, 2026

Celldex announces Phase 3 barzolvolimab trials meet primary and all key secondary endpoints - TradingView

Sep 22, 2026
pulisher
Sep 22, 2026

Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 - GlobeNewswire

Sep 22, 2026
pulisher
Sep 22, 2026

Celldex Therapeutics stock gains as analysts target USD 56.42 - AD HOC NEWS

Sep 22, 2026
pulisher
Sep 21, 2026

Celldex Reports Positive Phase 3 Results for Barzolvolimab - Intellectia AI

Sep 21, 2026
pulisher
Sep 18, 2026

Celldex Therapeutics stock gains as analysts lift expectations - AD HOC NEWS

Sep 18, 2026
pulisher
Sep 10, 2026

Celldex at Cantor conference: barzolvolimab data loom By Investing.com - Investing.com Canada

Sep 10, 2026
pulisher
Sep 08, 2026

Celldex to Present at Upcoming Investor Conference - The Manila Times

Sep 08, 2026
pulisher
Sep 08, 2026

Celldex's investor talk will stream online Sept. 10 - Stock Titan

Sep 08, 2026
pulisher
Aug 26, 2026

Celldex (CLDX) Q2 2026 Earnings: The Available Earnings Metric Delivers a Beat in Latest Trading; Post-Earnings: The Stock Records a 1.60% Increase at the CloseGuidance Downgrade Alert - dars.gov.et

Aug 26, 2026
pulisher
Aug 24, 2026

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX) - Prime Publishers, Inc.

Aug 24, 2026
pulisher
Aug 21, 2026

Celldex Therapeutics, Inc. Revenue Breakdown – NASDAQ:CLDX - TradingView

Aug 21, 2026
pulisher
Aug 20, 2026

Celldex (CLDX) Quarterly Results: Profit Per Share Clears Its Benchmark on the Day; Market Reaction - vinanet.vn

Aug 20, 2026
pulisher
Aug 20, 2026

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat

Aug 20, 2026
pulisher
Aug 19, 2026

Celldex (CLDX) Momentum: Adds 0.32% to Close at $41.92 in the Current Update; Range Check - vinanet.vn

Aug 19, 2026
pulisher
Aug 18, 2026

Celldex Therapeutics, Inc. $CLDX Shares Acquired by Bank of America Corp DE - MarketBeat

Aug 18, 2026
pulisher
Aug 15, 2026

Celldex Therapeutics (CLDX) Slips 1.55% to $41.95 as Clinical-Stage Biotech ConsolidatesMomentum Surge Alerts - vinanet.vn

Aug 15, 2026
pulisher
Aug 14, 2026

Kynam Capital (CLDX) group discloses 6.78% Celldex Therapeutics ownership stake - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

T. Rowe Price Associates (CLDX) discloses 6.0% Celldex Therapeutics ownership on Schedule 13G - Stock Titan

Aug 14, 2026
pulisher
Aug 12, 2026

Sei Investments Co. Purchases Shares of 38,152 Celldex Therapeutics, Inc. $CLDX - MarketBeat

Aug 12, 2026
pulisher
Aug 11, 2026

Why Celldex Therapeutics (CLDX) Is Up 10.7% After Wider Losses And Barzolvolimab Phase 3 Progress - Sahm

Aug 11, 2026
pulisher
Aug 11, 2026

HC Wainwright Issues Optimistic Forecast for CLDX Earnings - MarketBeat

Aug 11, 2026
pulisher
Aug 11, 2026

Quantinno Capital Management LP Buys 42,158 Shares of Celldex Therapeutics, Inc. $CLDX - MarketBeat

Aug 11, 2026
pulisher
Aug 11, 2026

Celldex Therapeutics (NASDAQ:CLDX) Reaches New 1-Year HighTime to Buy? - MarketBeat

Aug 11, 2026
pulisher
Aug 10, 2026

Assenagon Asset Management S.A. Buys 642,171 Shares of Celldex Therapeutics, Inc. $CLDX - MarketBeat

Aug 10, 2026

Celldex Therapeutics Inc (CLDX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$117.83
price down icon 3.06%
$35.80
price down icon 0.91%
$58.21
price down icon 0.14%
$255.96
price up icon 2.55%
ONC ONC
$360.85
price up icon 0.24%
$204.97
price up icon 2.56%
大文字化:     |  ボリューム (24 時間):